Next 10 |
home / stock / antx / antx articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or th...
U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 3...
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 ...
BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating AN2 Therapeutics, Inc. (NASDAQ:ANTX) for potential securities law...
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market opening Monday, the Dow tr...
AN2 Therapeutics Inc (NASDAQ:ANTX) has voluntarily paused Phase 3 enrollment in the Phase 2/3 trial (EBO-301) evaluating epetraborole in treat...
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monday.com Ltd. (NASDAQ: ...
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indic...
News, Short Squeeze, Breakout and More Instantly...
AN2 Therapeutics Inc. Company Name:
ANTX Stock Symbol:
NYSE Market:
2024-04-02 05:30:04 ET JMP Securities analyst issues OUTPERFORM recommendation for ANTX on April 2, 2024 02:23AM ET. ANTX was trading at $3.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recom...
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and inve...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...